Significantly reducing the cost of biopharmaceuticals, the world's first! 30000 liters of ultra large scale mammalian cell production line delivered to Lingang | Biology | Production Line in Shanghai
On June 30th, the High Quality Development Summit of the Biomedical Industry was held in the Lingang New Area. At the meeting, Shanghai Bibo Biomedical Engineering Co., Ltd. announced that after 18 months of hard work, its independently designed world's first 30000 liter ultra large scale mammalian cell production line has officially achieved project delivery recently.
According to Jiao Peng, Chairman of Bibo Biotechnology, the core equipment of the production line is a 30000 liter mammalian cell bioreactor, which has successfully surpassed the previous 20000 liter reactor technology in terms of scale. It is the world's first and largest single tank volume, filling the gap in China's large-scale biopharmaceutical production technology and marking China's entry into the international advanced ranks in large-scale commercial production of biopharmaceuticals.
"As a result, Bibo Biotechnology has become the world's first and largest new generation biopharmaceutical production platform." Jiao Peng said, "With the technology of this large-scale mammalian cell production line, it is expected to alleviate the trend of global biopharmaceutical production capacity gap expanding year by year, significantly reduce the production cost of biopharmaceuticals, improve drug accessibility, and enable more people to use and afford good drugs."
Yang Shengli, an academician of the CAE Member, said that at present, China's production of biological drugs is heavily dependent on the imported 2000L disposable bioreactor, which has high operating costs and is vulnerable to external constraints on equipment and consumables. The mainstream equipment used for large-scale commercial production of biopharmaceuticals in European and American countries is a 15000 liter large-scale stainless steel bioreactor production line. Previously, China had been in a blank state in this field.
"The completion of the 30000 liter large-scale mammalian cell production line by Bibo Biotechnology not only completes the leap of China's biopharmaceutical industry towards the international mainstream 15000 liter large-scale production line technology, but also achieves the first 30000 liter large-scale bioreactor production line technology internationally. At the same time, achieving independent control of key core equipment will become an important support for China's modern biopharmaceutical industry system and play a leading role in the international biopharmaceutical manufacturing trend." Yang Shengli said.
The reporter learned that since 2021, in order to strengthen the production capacity supply of biopharmaceutical commercialization, the four major international leading CDMO enterprises have announced investment of more than 13 billion US dollars and the construction of over 1.6 million liters of production capacity. However, there are no enterprises in China that have truly entered the field of large-scale commercial production of biopharmaceuticals. Jiao Peng revealed that Bibo Biotech will leverage its fully independent intellectual property rights in the world's first 30000 liter ultra large bioreactor production line technology, as well as its unique PanFlex ®- Engineering technology system, building a biopharmaceutical production base with a production capacity of over 1 million liters, striving to become a leader in the fourth wave of global biopharmaceutical manufacturing, and serving the global pharmaceutical market.